The FDA recently released draft guidance on DCTs. Whilst this is a significant step towards providing a clear framework for implementing DCTs, some parts could be expanded on for the industry to take full advantage of their potential. We reflected on our learnings from delivering DCTs to highlight three key areas we think can benefit from additional detail: participant engagement, recruitment and retention, and the handling of investigational products.

Hear from Chris Williams, a friend of Lindus Health and founder of Tiggo Care - a community care business supporting vulnerable adults in London - about best practices for conducting clinical research in the community.

Mike Pace stops by our virtual fireplace to share tips on how to achieve payor reimbursement for DTx products and encourage adoption among clinicians in the most attractive international markets.

To work on innovative trials and accelerate access to treatments. To tackle disparities in research accessibility. To use technology to accelerate studies and work with a motivated team. Hear more from our VP of Clinical Operations, Emma Ogburn PhD, on why she joined Lindus Health.

To build great products, we need a set of underlying principles grounded in hard reality. What matters most in clinical trial delivery? Is it regulatory approval? Is it patient safety? Of course, these are non-negotiable, hard requirements. But to answer our question fully, we need to take a step back to get a broader view of what is at the heart of running a clinical trial.

In this blog post, we talk about ISOs, what they are, and why they matter in the Life Sciences sector. If you're in this industry, you've likely heard the term ISO thrown around, but do you know what it really means?